Search clinical trials for: cenegermin-bkbj

Total 16 results

Tufts Medical Center
Dompé Farmaceutici S.p.A

Withdrawn

NGF Treatment for Patients With Neuropathic Corneal Pain

Neuropathy | Corneal Disease

United States
Stanford University

Completed

Nerve Growth Factor for the Treatment of Cornea Disease

Neurotrophic Keratitis

United States
Dompé Farmaceutici S.p.A
Dompé US

Completed

Study to Evaluate OXERVATE™ in Patients With Stage 1 Neurotrophic Keratitis (DEFENDO)

Neurotrophic Keratitis

United States
Dompé Farmaceutici S.p.A

Active, not recruiting

Open-label Trial to Evaluate Efficacy and Safety of rhNGF on Corneal Thickness Via AS-OCT in Neurotrophic Keratitis (IMAGO)

Neurotrophic Keratitis | Corneal Ulcer | Neurotrophic Keratopathy

United States
Sight Medical Doctors PLLC
Dompé, US, Inc.

Recruiting

OCT Evaluation of Neurotrophic Ulcer Following Treatment With Oxervate

Neurotrophic Keratitis | Neurotrophic Ulcer | Neurotrophic Corneal Ulcer | Neurotrophic Keratoconjunctivitis

United States
Dompé Farmaceutici S.p.A
Cromsource

Completed

Study to Evaluate Safety and Efficacy of rhNGF Eye Drops Solution Versus Vehicle in Patients With Glaucoma (NGF-Glaucoma)

Glaucoma

United States
Dompé Farmaceutici S.p.A

Completed

A Study to Evaluate Safety and Efficacy of rhNGF Eye Solution vs Vehicle in Patients With Moderate to Severe Dry Eye

Dry Eye Syndrome

United States
Dompé Farmaceutici S.p.A

Completed

An 8-week Study to Evaluate Safety and Efficacy of NGF Eye Drops Solution Versus Vehicle in Patients With Dry Eye

Dry Eye

United States
University of California, Los Angeles

Recruiting

Corneal Nerves After Treatment With Cenegermin

Neurotrophic Keratitis

United States
Dompé Farmaceutici S.p.A

Completed

Safety and Efficacy Study on Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (PROTEGO-1 Study) (NGF0121)

Dry Eye

United States, Italy
Dompé Farmaceutici S.p.A

Completed

Evaluation of Efficacy of 20 µg/ml rhNGF New Formulation (With Anti-oxidant) in Patients With Stage 2 and 3 NK

Neurotrophic Keratitis

United States
Dompé Farmaceutici S.p.A
Cromsource

Completed

Study to Evaluate Safety, Tolerability & PK of rhNGF in Healthy Volunteers

Healthy Volunteers

United States
Dompé Farmaceutici S.p.A

Recruiting

DEFENDO Long Term Follow-up Study in Stage 1 NK Patients (DEFENDO)

Neurotrophic Keratitis

United States
Dompé Farmaceutici S.p.A

Completed

Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (NGF0221)

Dry Eye Syndrome

United States, Italy
G. d'Annunzio University

Completed

An 8-week Follow-up to Evaluate the Renewal of Corneal Nerves Structure and Function in Patients With Neurotrophic Keratopathy Treated With Recombinant Human Nerve Growth Factor (rhNGF) Eyedrops

Neurotrophic Keratopathy

Italy
Dompé Farmaceutici S.p.A
Cross Research S.A.

Completed

Safety and Efficacy of rhNGF Eye Drops at Different Doses in Patients With Dry Eye

Dry Eye Syndrome

Austria

3

Subscribe